Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 4R00GM159353-02 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of General Medical Sciences (NIGMS) | NIH |
Not provided
Not provided
Not provided
SpiCoH is a phase IIa, single center, open-label, clinical trial of intermittent normobaric hyperoxia in mechanically ventilated patients with traumatic cervical and/or thoracic spinal cord injury.
Intermittent normobaric hyperoxia (NBH) by increasing FiO2 to 100% for a duration of 4.5h (270 min), twice daily over five consecutive days. Instead of fixed 12-hour intervals between sessions, the two daily treatments will follow a pre-specified interval: a minimum of 1.5h (90min) between sessions for treatment B, and 10h (600min) for treatment A.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Experimental | Normobaric hyperoxia |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Normobaric Hyperoxia | Other | Intermittent normobaric hyperoxia (NBH) by increasing FiO2 to 100% for a duration of 4.5h (270 min), twice daily over five consecutive days. Instead of fixed 12-hour intervals between sessions, the two daily treatments will follow a pre-specified interval: a minimum of 1.5h (90min) between sessions for treatment B, and 10h (600min) for treatment A. |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility of early normobaric hyperoxic therapy | Proportion of subjects receiving first normobaric hyperoxia therapy. | 24 hours from injury |
| Preliminary efficacy of intermittent normobaric hyperoxia in achieving high oxygen concentrations systemically | Serial PaO2 | From enrollment to the end of intervention period at 5 days |
| Preliminary safety of intermittent normobaric hyperoxia | Four-point end-organ toxicity surveillance. | From completion of first treatment to end of 6 month follow up period |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility of intermittent therapeutic hyperoxemia and elevated oxygen concentration | Serial PaO2. Proportion of subjects receiving all 10 planned normobaric hyperoxia treatments. | From enrollment to the end of intervention period at 5 days |
| Exploratory safety objectives |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Andrew Kline | Contact | 352-273-9000 | andrew.kline@neurosurgery.ufl.edu | |
| Ralisa Pop | Contact | (352) 294-5693 | Ralisa.Pop@neurology.ufl.edu |
| Name | Affiliation | Role |
|---|---|---|
| Carolina Maciel, MD, MSCR | University of Florida | Principal Investigator |
| Katharina Busl, MD, MS | University of Florida | Principal Investigator |
| Daryl Fields, MD, PhD |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Florida | Recruiting | Gainesville | Florida | 32610 | United States |
Individual participant data (IPD) underlying the primary results of this study-including de-identified clinical, physiologic, and outcome variables-will be made available following publication of the main results. Data will be shared in accordance with institutional policies and applicable regulations after all direct identifiers have been removed using a standardized de-identification protocol. The curated dataset, accompanying data dictionary, and analytic code (when applicable) will be deposited in the National Spinal Cord Injury Statistical Center (https://sites.uab.edu/nscisc/), where they will be accessible under a controlled-access model. Qualified researchers may request access by submitting a brief proposal outlining the intended use of the data; requests will be reviewed by the study team to ensure scientific validity and compliance with participant privacy protections. Data will remain available for the duration required by institutional policy.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018496 | Hyperoxia |
| ID | Term |
|---|---|
| D012818 | Signs and Symptoms, Respiratory |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
open label
Not provided
Not provided
Not provided
Not provided
|
Rates of study termination from demonstrated signs of organ injury attributable to hyperoxia determined by safety monitoring board |
| From enrollment to end of 6 month follow up period |
| Feasibility - Timely Placement of Lumbar Drain | Proportion of subjects with lumbar drain placed before initiation of normobaric hyperoxia. | Time of injury to 24hr post injury. |
| Feasibility - Completion of Required Monitoring Lines | Proportion of subjects with lumbar drain and arterial line for the duration of 5-day intervention period. | Day 0 to day 5 |
| Protocol Adherence - Sampling Deviations | Rate of protocol violations or deviations related to missing samples or samples obtained outside the planned schedule for blood and/or CSF. | Enrollment to end of 6 month follow up period |
| Sample Handling - Discarded Specimens | Rate of discarded CSF or blood samples | From enrollment to end of 6 month follow up period |
| University of Florida |
| Principal Investigator |